Background
American Indian/Alaska Native (AI/AN) people experience disproportionately high rates of hepatitis C virus (HCV) infection. In 2024, an FDA-approved point-of-care (PoC) HCV RNA test was integrated into community-based screening efforts within Cherokee Nation to expand access and improve linkage to care for underserved, high-risk individuals. The objective of this study is to assess how PoC versus laboratory-based standard-of-care (SoC) HCV screening protocols affect time to treatment initiation.
Methods
This retrospective cohort study analyzed electronic medical record data from a tribal health system to evaluate the impact of PoC versus SoC hepatitis C virus (HCV) RNA testing on time to treatment initiation. The study population included AI/AN adults aged 22 years or older who underwent HCV RNA testing between October 30, 2024, and August 31, 2025. The primary outcome was the time from an RNA-positive result to initiation of HCV treatment. The Wilcoxon rank-sum test was used to assess differences in time to treatment between groups, and the chi-square test was used to compare treatment initiation rates and history of substance use disorder (SUD).
Results
A total of 24 active HCV cases were diagnosed via PoC testing and 127 through SoC screening. Treatment initiation rates were in 70.8% (17 out of 24) in the PoC group and 63.8% (81 out of 127) in the SoC group (p = 0.5). Among those treated, 76% in the PoC group and 91% in the SoC groups had a history of SUD (p=0.08). Importantly, a significantly greater proportion of treated individuals in the PoC group (8 of 17, 47.1%) commenced treatment on the same day of diagnosis, compared to 12 out of 81 (14.8%) in the SoC screening group (p = 0.003). Furthermore, the mean time to treatment initiation was significantly shorter in the PoC group (18.2 days) than in the SoC screening group (33.7 days) (p = 0.003).
Conclusions
Point-of-care testing for HCV yields a comparable treatment initiation rate to SoC screening but significantly reduces time to treatment including same-day treatment initiation. These results highlight PoC testing’s potential to expedite access to HCV care and improve treatment engagement, particularly in high-risk groups such as individuals with substance use disorders and intravenous drug users. Rapid treatment initiation in these populations is critical to reducing HCV transmission and advancing elimination efforts.